BBIO May 2024 30.000 put
| Previous close | 0.1000 |
| Open | 0.4400 |
| Bid | 0.0000 |
| Ask | 0.9500 |
| Strike | 30.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 6.66k |
GlobeNewswireBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on May 9, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 24 new employees in restricted stock units for an aggregate of 97,557 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restrict
- GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page
- GlobeNewswire
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM participants enrolled with Stage 4 chronic kidney disease (CKD) (N=21), acoramidis treatment was associated with proportionally fewer deaths compared with placebo, with no safety signals of potential clinical concern
